{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:33:13Z","timestamp":1790609593813,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ymgmr.2021.100758","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T07:11:01Z","timestamp":1618816261000},"page":"100758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II"],"prefix":"10.1016","volume":"27","author":[{"given":"Ryuji","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Yoden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Imakiire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ymgmr.2021.100758_bb0005","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1073\/pnas.87.21.8531","article-title":"Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA","volume":"87","author":"Wilson","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgmr.2021.100758_bb0010","first-page":"107","article-title":"Mucopolysaccharidosis type II, Hunter\u2019s syndrome","volume":"12","author":"Tylki-Szyma\u0144ska","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ymgmr.2021.100758_bb0015","series-title":"The Metabolic & Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The Mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100758_bb0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10545-008-0878-x","article-title":"Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed","volume":"31","author":"Al Sawaf","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100758_bb0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100758_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100758_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100758_bb0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/gim.2013.162","article-title":"A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4\u20137.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy","volume":"16","author":"Giugliani","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2021.100758_bb0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100758_bb0050","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic Mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2021.100758_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2021.01.027","article-title":"Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice","author":"Morimoto","year":"2021","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100758_bb0060","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic Mucopolysaccharidosis II: a phase 1\/2 trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100758_bb0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2021.100758_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2021.03.019","article-title":"Iduronate-2-sulfatase fused with anti-human transferrin receptor antibody, pabinafusp alfa, for treatment of neuronopathic and non-neuronopathic mucopolysaccharidosis II: report of a phase 2 trial in Brazil","author":"Giugliani","year":"2021","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100758_bb0075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/bab.1617","article-title":"Progress in biopharmaceutical development","volume":"65","author":"Kesik-Brodacka","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100758_bb0080","first-page":"372","article-title":"Antibody-mediated targeting of the transferrin receptor in cancer cells","volume":"73","author":"Luria-P\u00e9rez","year":"2016","journal-title":"Bol. Med. Hosp. Infant. Mex."},{"issue":"2 Pt B","key":"10.1016\/j.ymgmr.2021.100758_bb0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.molimm.2015.07.001","article-title":"Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1","volume":"67","author":"Leoh","year":"2015","journal-title":"Mol. Immunol."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100758_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10408444.2011.653487","article-title":"The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy","volume":"42","author":"DeSesso","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100758_bb0095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-engineering for modulated effector functions-improving antibodies for cancer treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"10","key":"10.1016\/j.ymgmr.2021.100758_bb0100","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3390\/cancers12103041","article-title":"Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies","volume":"12","author":"van der Horst","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ymgmr.2021.100758_bb0105","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1021\/acs.molpharmaceut.8b00730","article-title":"Blood-brain barrier transport, plasma pharmacokinetics, and neuropathology following chronic treatment of the rhesus monkey with a brain penetrating humanized monoclonal antibody against the human transferrin receptor","volume":"15","author":"Pardridge","year":"2018","journal-title":"Mol. Pharm."},{"issue":"19","key":"10.1016\/j.ymgmr.2021.100758_bb0110","first-page":"6295","article-title":"Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects","volume":"50","author":"White","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymgmr.2021.100758_bb0115","first-page":"121","article-title":"Transferrin receptor as a potential therapeutic target","volume":"45","author":"Trowbridge","year":"1988","journal-title":"Prog. Allergy"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921000525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921000525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:13Z","timestamp":1762001533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921000525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":23,"alternative-id":["S2214426921000525"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100758","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100758"}}